Warnex Inc. (TSX: WNX) announced today that it has been advised that Bio-Rad Laboratories and MJ Research have reached a settlement agreement with Applied Biosystems, an Applera Corporation business, which allows them to resume the manufacturing, selling and servicing of PCR thermal cyclers in the United States. Currently, the Warnex(TM) Rapid Pathogen Detection System incorporates MJ Research PCR thermal cyclers in its platform for performing proprietary pathogen detection tests.
More details concerning this settlement agreement are disclosed in the press release issued today by Applied Biosystems, which may be consulted at www.appliedbiosystems.com.
About Warnex
Warnex (www.warnex.ca) is a publicly traded (TSX: WNX) Canadian biotechnology company devoted to protecting public health by providing advanced diagnostic and quality control products and services to the pharmaceutical, agri-food, and healthcare sectors. Warnex's genomics-based technology offers a versatile detection platform that produces accurate results rapidly, using Real-Time PCR technology combined with unique genetic markers and software. Applications range from pathogen detection in foods to GMO testing. Our development pipeline includes applications in the detection of viruses, toxins, yeasts, and fungi, as well as meat speciation and bioterrorism. Warnex's profitable and growing analytical, bioanalytical, and clinical service groups offer a variety of quality control services, method development and validation, contract R&D, bioavailability and bioequivalence studies for clinical trials, and medical laboratory testing.
Warnex is a trademark of Warnex Inc.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to the early commercialization of Warnex products, intellectual property and licensing, R&D of new Warnex products, manufacturing and laboratory facilities, suppliers, key employees, key customers, financial resources and credit risk, government regulations, foreign currency risk and volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in the Management's Discussion and Analysis for the third quarter ended on September 30, 2005, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.
%SEDAR: 00010099EF
For further information: Mark J. Busgang, President & CEO, Warnex Inc., Tel: (450) 663-6724 x.310, mbusgang@warnex.ca; Mike Polonsky, Investor Relations, The Equicom Group Inc., Tel: (416) 815-0700 x.231, mpolonsky@equicomgroup.com